Sera Prognostics
SALT LAKE CITY, UT · Founded 2008 · CIK 0001534969 · Medtech · Public
Prenatal diagnostic tests using blood biomarkers to assess pregnancy risks
seraprognostics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $150M
- 9 Form D · Apr 2021
- 66 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 5 granted · 35 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201120132015201720192021202320252027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $10,229,985 | |
| Private capital raised | Form D · SEC | $1,250,000 | |
| Private capital raised | Form D · SEC | $9,156,865 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $22,737,347 | |
| Private capital raised | Form D · SEC | $7,573,369 | |
| Private capital raised | Form D · SEC | $6,400,000 | |
| Private capital raised | Form D · SEC | $25,770,453 | |
| Private capital raised | Form D · SEC | $61,500,000 |
Form D · SECPress
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1728 | NUVAIRA, INC. | — | $164M |
| 1729 | Nicolaos Christodoulides | — | — |
| 1730 | SURGISENSE CORPORATION | — | — |
| 1731 | Sera Prognostics | — | $150M |
| 1732 | Trevi Therapeutics, Inc. | — | $118M |
| 1733 | EPOULOSIS THERAPEUTICS, INC. | — | — |
| 1734 | ANDE Corp | — | $109M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Press
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICERPRNewswire
Founders & Team
- Elizabeth CanisDirector
- Gregory CritchfieldDirector · Executive Officer
- Dennis FarrarDirector
- Douglas FisherDirector · Executive Officer
- Kim KamdarDirector
- Charles KennedyDirector
- Michael MinahanDirector
- Mansoor MirzaDirector
- Jay MoyesExecutive Officer
- Richard NovakDirector
- Arnold Oronsky, Ph.D.Director
- Mark OstrowskiExecutive Officer
- Joshua PhillipsDirector
- Andrew SauterExecutive Officer
- Joseph SilettoDirector
- Ryan TrimbleDirector
- Marcus WilsonDirector
Patents
- Biomarkers And Methods For Predicting Preterm Birthgranted
- Biomarker Panels And Methods For Predicting Preeclampsiaapplication
- Shbg And IBP4 Antibodies And Methods Using Sameapplication
- Biomarkers For Predicting Preterm Birth Due To Preterm Premature Rupture Of Membranes (pprom) Versus Idiopathic Spontaneous Labor (ptl)application
- Biomarker Pairs For Predicting Preterm Birthapplication
- Biomarker Pairs And Triplets For Predicting Preterm Birthapplication
- Biomarker Pairs For Predicting Preterm Birthgranted
- Pregnancy clock proteins for predicting due date and time to birthapplication
- Pregnancy clock proteins for predicting due date and time to birthgranted
- Biomarkers For Predicting Preterm Birth Due To Preterm Premature Rupture Of Membranes (pprom) Versus Idiopathic Spontaneous Labor (ptl)application
- Biomarkers And Methods For Predicting Preeclampsiaapplication
- Biomarker Pairs For Predicting Preterm Birthgranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.